Recruiting PHASE1 INTERVENTIONAL 6-arm NCT06344715

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

A Phase 1, Multi-center, Open-label, Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10, GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sponsor: SL VAXiGEN

Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions GX-I7 Pembrolizumab SL-T10

Updated 4 times since 2024 Last updated: Mar 27, 2024 Started: Oct 17, 2022 Primary completion: Oct 31, 2024 Completion: Oct 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic Castration-resistant Prostate Cancer (mCRPC) and is currently actively recruiting participants. SL VAXiGEN leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SL VAXiGEN

Data source: SL VAXiGEN

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea